58 results
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
and other pharmacovigilance activities conducted under an established quality system, advertising, packaging and labelling, patient package leaflets … package is designed to reduce the risk of excessively risk-oriented behavior, to discourage initiatives focused on short-term results which might
6-K
EX-99
BLRX
Bioline Rx Ltd
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA submission.
In March 2022, we
6-K
EX-99
BLRX
Bioline Rx Ltd
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
, is sufficient to support an NDA submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
, is sufficient to support an NDA submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA
6-K
EX-99
7svsju lic
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
424B5
yt6h1rni
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
i6ppqiy cb
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
8z6kez3w2
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
5vbasprl 86jhongm
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
m25ym7s5ml2
16 Mar 22
BioLineRx Reports Fourth Quarter 2021 Financial Results
7:11am
6-K
EX-99
lzjhc
18 Jan 22
BioLineRx Announces Successful Completion of Pre-NDA
7:11am
6-K
EX-99
2evca bmu6y2y
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
6-K
EX-1
cr6ylf2zfqkx
28 May 19
Current report (foreign)
7:04am